Fengxin Zheng, Suiqing Mai, Xiaolin Cen, Pei Zhao, Wenjie Ye, Jiale Ke, Shiqin Lin, Huazhong Hu, Zitao Guo, Shuqin Zhang, Hui Liao, Ting Wu, Yuanxin Tian, Qun Zhang, Jianxin Pang, Zean Zhao
The development of XOD/URAT1 dual target inhibitors has emerged as a promising therapeutic strategy for the management of hyperuricemia. Here, through virtual screening, we have identified digallic acid as a novel dual target inhibitor of XOD/URAT1 and subsequently evaluated its pharmacological properties, pharmacokinetics, and toxicities. Digallic acid inhibited URAT1 with an IC50 of 5.34 ± 0.65 μM, which is less potent than benzbromarone (2.01 ± 0.36 μM) but more potent than lesinurad (10...
April 23, 2024: Bioorganic Chemistry